Biliary Tract Cancer Market Set to Grow at a Strong CAGR Through 2036 with 25+ Companies Advancing Novel Therapies | DelveInsight

DelveInsight's report titled "Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2036" provides a comprehensive analysis of Biliary Tract Cancer, including both historical and projected epidemiological data, along with market trends across the United States, EU4 countries (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Access a complimentary sample of the Biliary Tract Cancer Market Report:
https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Biliary Tract Cancer Market Report:
• The Biliary Tract Cancer market is projected to expand at a notable CAGR throughout the forecast period (2022-2036).
• The Biliary Tract Cancer (BTC) market was valued at approximately USD 1,300 million in 2025 and is projected to reach nearly USD 3,500 million by 2036, reflecting substantial growth over the forecast period, according to DelveInsight.
• In January 2026, Summit Therapeutics Inc. announced that the US FDA accepted its Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for treating EGFR-mutated advanced or metastatic non-squamous NSCLC following TKI therapy. The FDA has set a PDUFA action date of November 14, 2026. Meanwhile, Akeso continues to advance multiple Phase III trials of ivonescimab across additional cancers, including biliary tract cancer.
• In September 2025, Roche reported CE IVDR approval for expanded indications of its VENTANA HER2 (4B5) assay. This diagnostic helps identify HER2-ultralow expression in metastatic breast cancer patients, making them eligible for ENHERTU, a HER2-targeting ADC developed by Daiichi Sankyo and AstraZeneca.
• In April 2025, Compass Therapeutics announced that its Phase 2/3 COMPANION-002 trial evaluating tovecimig with paclitaxel in advanced biliary tract cancer achieved its primary endpoint with statistically significant results.
• In January 2025, findings from the Phase 3 SWOG S1815 trial showed that adding nab-paclitaxel to gemcitabine and cisplatin did not significantly improve survival outcomes in newly diagnosed advanced BTC patients.
• In December 2024, Jazz Pharmaceuticals received accelerated FDA approval for Ziihera (zanidatamab-hrii) for treating previously treated, unresectable, or metastatic HER2-positive BTC patients.
• In November 2024, CTX-009, a bispecific antibody targeting DLL4 and VEGF-A pathways, demonstrated promising anti-tumor activity across multiple cancers. The COMPANION-002 study is assessing CTX-009 plus paclitaxel versus paclitaxel alone in advanced BTC patients.
• In August 2024, Compass Therapeutics confirmed the completion of patient enrollment in its COMPANION-002 Phase 2/3 trial involving 150 BTC patients.
• In June 2024, Bold Therapeutics presented encouraging Phase 2 safety and efficacy results for BOLD-100 in advanced BTC and gastric cancer at the ASCO annual meeting.
• Chemotherapy remains the primary treatment approach; however, emerging therapies such as CX-4945 and CTX-009 are expected to significantly reshape the treatment landscape over the forecast period.
• In 2023, the United States accounted for the largest share of the BTC market within the 7MM, contributing approximately 48% of the total market.
• The US also represented around 30% of total incident BTC cases in 2023, marking the highest patient population among the studied regions.
• The majority of BTC cases in the US occur in individuals aged 70-79 years, contributing nearly 30% of cases.
• TP53 mutations were the most frequently observed genetic alteration in BTC cases in 2023, followed by KRAS mutations.
• Leading companies involved in BTC include Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences, Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Bristol-Myers Squibb, Leap Therapeutics, Compass Therapeutics, Boehringer Ingelheim, ZielBio, GeneQuantum Healthcare, BioNTech, SOTIO Biotech, Carisma Therapeutics, Rain Oncology, Avacta Life Sciences, DualityBio, among others.
• Key therapies in development and use include Keytruda, Imfinzi, Futibatinib, Melphalan, Tasurgratinib, TT-00420, Derazantinib, Lenvatinib, Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and more.
• The BTC market is expected to grow substantially due to increasing disease prevalence and improved awareness. Additionally, the introduction of pipeline therapies across different stages is likely to transform the overall market landscape.

Biliary Tract Cancer Overview
Biliary Tract Cancer (BTC) is a rare yet aggressive malignancy that develops in the bile ducts, which transport bile from the liver to the small intestine. It encompasses cancers of intrahepatic and extrahepatic bile ducts, as well as gallbladder cancer. Symptoms are often nonspecific, including jaundice, abdominal discomfort, and weight loss, leading to delayed detection. BTC is frequently diagnosed at advanced stages, complicating treatment. Available treatment options include surgery, chemotherapy, and targeted therapies, depending on disease stage and location.

To explore detailed insights on market outlook, treatment trends, drug uptake, and epidemiology:
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Biliary Tract Cancer Epidemiology
Across the 7MM, Japan reported the highest incidence of Biliary Tract Cancer (BTC) with around 22,000 cases in 2025, and this number is expected to grow steadily at a CAGR of 1.2%. Within Europe, Italy had the highest BTC cases among the EU4 and the UK, followed by the UK and Germany, while Spain recorded the lowest incidence. In the United States, individuals aged 65 and above accounted for nearly 65% of total cases, with those aged 45-64 contributing about 30% and patients under 44 representing only 5%.
Overall, BTC remains a rare but highly fatal group of cancers across the 7MM, with cholangiocarcinoma contributing significantly to the disease burden. The epidemiological patterns vary widely due to differences in risk factors, healthcare systems, diagnostic approaches, and classification standards. Japan continues to show a comparatively higher burden, likely due to a greater prevalence of biliary diseases and stronger clinical awareness of BTC.

Biliary Tract Cancer Epidemiology Segmentation:
The report segments BTC epidemiology across the 7MM based on:
• Overall prevalence of Biliary Tract Cancer
• Severity-based prevalence distribution
• Gender-specific prevalence patterns
• Diagnosed cases categorized into episodic and chronic BTC

Download the report to identify key drivers shaping epidemiological trends:
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Biliary Tract Cancer Drug Uptake and Pipeline Development
Tinengotinib: TransThera Sciences
Tinengotinib is an investigational oral multi-kinase inhibitor being developed for cholangiocarcinoma, particularly for patients with FGFR-altered tumors who have progressed following prior treatments. It targets multiple pathways, including FGFR1-3, VEGFR, Aurora kinases, and JAK kinases, thereby inhibiting tumor proliferation, angiogenesis, and resistance mechanisms. Clinical findings were presented at the ASCO Gastrointestinal Cancers Symposium 2026, and the therapy is expected to launch in the US by 2027.

Rilvegostomig: AstraZeneca
Rilvegostomig is a novel dual-checkpoint bispecific antibody designed to simultaneously block PD-1 and TIGIT on the same immune cell, enhancing antitumor immune responses and supporting sustained clinical benefits. Its TIGIT-targeting component is based on COM902, originally developed by Compugen. In December 2025, Compugen entered into an agreement with AstraZeneca to monetize a portion of its future royalties and revised their 2018 exclusive licensing agreement to further strengthen their immuno-oncology development pipeline.

Key Biliary Tract Cancer Therapies and Companies
• Keytruda (pembrolizumab): Merck Sharp & Dohme
• Imfinzi (durvalumab): AstraZeneca
• Futibatinib (TAS-120): Taiho Oncology
• Melphalan: Delcath Systems
• Tasurgratinib (E7090): Eisai
• TT-00420: TransThera Sciences
• Derazantinib (ARQ 087): Basilea Pharmaceutica
• Lenvatinib: Eisai & Merck
• Zanidatamab: Zymeworks & BeiGene
• XmAb20717: Xencor
• Nivolumab + DKN-01: Bristol-Myers Squibb & Leap Therapeutics
• CTX-009: Compass Therapeutics
• MEDI5752: AstraZeneca
• Brigimadlin: Boehringer Ingelheim
• ZB131: ZielBio
• GQ1001: GeneQuantum Healthcare
• BNT141: BioNTech
• SO-C101: SOTIO Biotech
• CT-0508: Carisma Therapeutics
• RAIN-32: Rain Oncology
• AVA6000: Avacta Life Sciences
• DB-1303: DualityBio

Explore Biliary Tract Cancer therapies expected to capture significant market share:
https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Biliary Tract Cancer Market Drivers
• Increasing global incidence of BTC, particularly cholangiocarcinoma, fueled by aging demographics and lifestyle risks
• Significant unmet medical need due to late diagnosis and limited efficacy of conventional treatments
• Progress in molecular diagnostics enabling targeted and precision therapies
• Rising R&D investments and expanding clinical trial activities in immunotherapy and targeted treatments
• Supportive regulatory frameworks including orphan drug incentives and accelerated approvals

Biliary Tract Cancer Market Challenges
• Late-stage diagnosis and tumor heterogeneity complicating treatment outcomes
• Limited availability of approved therapies, especially in early treatment lines
• High costs associated with drug development and treatment access
• Difficulty in conducting large-scale trials due to low prevalence and geographic differences
• Safety concerns and moderate response rates of existing therapies

Scope of the Biliary Tract Cancer Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Biliary Tract Cancer Companies: Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Eisai, Zymeworks, BeiGene, Xencor, Inc., Bristol-Myers Squibb, Leap Therapeutics, Inc., Compass Therapeutics, Boehringer Ingelheim, ZielBio, Inc., GeneQuantum Healthcare (Suzhou) Co., Ltd., BioNTech SE, SOTIO Biotech, Carisma Therapeutics Inc, Rain Oncology Inc, Avacta Life Sciences Ltd, DualityBio Inc., and others
• Key Biliary Tract Cancer Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Futibatinib (TAS-120), Melphalan, E7090 (tasurgratinib), TT-00420, ARQ 087 (Derazantinib), Lenvima (lenvatinib), Zanidatamab, XmAb20717, Nivolumab + DKN-01, CTX-009, MEDI5752, Brigimadlin, ZB131, GQ1001, BNT141, SO-C101, CT-0508, RAIN-32, AVA6000, DB-1303, and others
• Biliary Tract Cancer Therapeutic Assessment: Biliary Tract Cancer current marketed and Biliary Tract Cancer emerging therapies
• Biliary Tract Cancer Market Dynamics: Biliary Tract Cancer market drivers and Biliary Tract Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Biliary Tract Cancer Unmet Needs, KOL's views, Analyst's views, Biliary Tract Cancer Market Access and Reimbursement

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.